Integrative Oncogenomics of Multiple Myeloma (MM)
Official title: Integrative Oncogenomics of Multiple Myeloma
Funded at Dana-Farber Cancer Inst · NIH-11403915 · Data updated 2026-11-12
A translational research program at Dana-Farber brings together basic biology, clinical science, and genomic data to better understand and treat multiple myeloma.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2011 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $2,239,580 |
| NIH project number | 5P01CA155258-14 |
| Project ID | NIH-11403915 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with multiple myeloma, especially those undergoing high-dose therapy and concerned with MRD status and personalized risk profiling.
✕Less likely to help
Patients not living with multiple myeloma or those not eligible for high-dose therapy or MRD-guided approaches may not benefit.
What this research studies
This program consolidates basic science, clinical insights, and large-scale genomic analysis to map how myeloma develops and responds to treatment. Researchers have built targeted sequencing platforms, mapped the genomic and epigenomic landscape, and created a public data portal to share findings. The effort aims to clarify how high-dose therapy works with minimal residual disease and to develop risk models that guide personalized care. By analyzing clinically annotated patient samples and leveraging advanced genomics, the team seeks to improve prognosis and tailor therapies for MM patients.
Why it matters
Potential benefit: If successful, patients with multiple myeloma could receive more precise, effective treatment plans based on their genomic and MRD status.
How similar studies have gone: Previous work in MM has shown that MRD and genomic profiling can guide treatment; this program expands these findings with a larger, integrated approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Munshi, Nikhil C. — Dana-Farber Cancer Inst
- Study coordinator: Munshi, Nikhil C.
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.